Overview
- China’s drug regulator approved the sale of an invasive BCI described as a world first for commercial use, aimed at restoring hand grasp in people with quadriplegia from cervical spinal cord injuries.
- The system uses a minimally invasive extradural implant with wireless transmission to decode brain signals that control a robotic glove for basic hand movements.
- Eligible users must be 18–60 years old, at least one year post‑injury, medically stable for six months, unable to grasp, and still retain some upper‑arm function.
- Regulator‑cited clinical trials reported significant improvements in hand‑grasping ability and gains in quality of life for participants.
- Coverage differs on the approved manufacturer—some reports name Borui Kang Medical Technology and others cite Neuracle—while sector reaction included a share jump for Inkon Life Technology and a 500 million yuan StairMed funding round led by Alibaba.